HAE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
This valuation method assumes that the stock valuation will revert to its historical mean in terms of Price/Sales Ratio. The reason we use P/S Ratio instead of P/E Ratio or P/B Ratio is because Price/Sales Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median P/S Value is calculated as trailing twelve months (TTM) revenue per share times 10-Year median P/S ratio. Haemonetics Corp's revenue per share for the trailing twelve months (TTM) ended in Jun. 2016 was $17.767. Haemonetics Corp's 10-Year median P/S ratio is 2.40. Therefore, the Median P/S Value for today is $42.64.
As of today, Haemonetics Corp's share price is $36.68. Haemonetics Corp's median P/S value is $42.64. Therefore, Haemonetics Corp's Price to Median P/S Value Ratio for today is 0.87.
During the past 13 years, the highest Price to Median P/S Value Ratio of Haemonetics Corp was 1.43. The lowest was 0.56. And the median was 0.96.
Haemonetics Corp's Median P/S Value for today is calculated as
|Median P/S Value||=||Total Annual Sales / Shares Outstanding||*||10-Year Median P/S Ratio|
|=||Revenue per Share (TTM)||*||10-Year Median P/S Ratio|
10-Year Median P/S Ratio is 2.40.
Haemonetics Corp's revenue per share for the trailing twelve months (TTM) ended in Jun. 2016 was 4.292 (Sep. 2015 ) + 4.6 (Dec. 2015 ) + 4.76 (Mar. 2016 ) + 4.115 (Jun. 2016 ) = $17.767.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the companys value.
Haemonetics Corp's Price to Median P/S Value Ratio for today is calculated as
|Price to Median P/S Value||=||Share Price||/||Median P/S Value|
Haemonetics Corp Annual Data
Haemonetics Corp Quarterly Data